Acloproxalap

Acloproxalap is a quinoline-based aldehyde scavenger that can be used in studies of diseases with toxic aldehyde accumulation, such as inflammatory diseases of the eye and skin, respiratory diseases such as pneumonia, organ diseases, and viral infection-related syndromes[1][2].

Research Areas >> Cardiovascular Disease

Research Areas >> Infection

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

Acloproxalap (compound I-6) (100 or 200 mg/kg, i.p. or p.o., everyday, 6 days) can effectively improve inflammation of the colon in acute ulcerative colitis (UC) female Swiss Webster mice[1]. Animal Model: Acute ulcerative colitis (UC) in female Swiss Webster mice[1] Dosage: 100 mg/kg, 200 mg/kg Administration: Intraperitoneal injection for 100 mg/kg, oral gavage for 200 mg/kg; everyday; 6 days Result: Inhibited weight loss in intraperitoneal injection mice significantly while there was no significant difference in the oral gavage group compared to the control group. Both significantly reduced colonic histopathological parameters. Animal Model: Male non-naïve beagle dogs[2] Dosage: 3 mg/kg Administration: Intravenous injection; once Result: The pharmacokinetic parameters of Acloproxalap (compound I-1) Parameter Acloproxalap (compound I-1) t1/2 1.82 h Tmax 0.518 h Clearance 12.2 mL/kg/min steady-state volume 1385 mL/kg AUC0-t 4103 ng/mL*h AUC0‑inf_obs 4137 ng/mL*h Animal Model: Male non-naïve beagle dogs[2] Dosage: 10 mg/kg Administration: Oral gavage; once Result: The pharmacokinetic parameters of Acloproxalap (compound I-1) Parameter Acloproxalap (compound I-1) t1/2 3.02 h Tmax 0.518 h Cmax 3558 ng/mL AUC0-t 9361 ng/mL*h AUC0‑inf_obs 9546 ng/mL*h BioA 75%

[1]. Susan Macdonald, et al. Treatment of inflammatory disorders. US20190105322

[2]. Todd Brady, et al. Pharmaceutical formulations and uses thereof. WO2021231792